AbbVie’s Rinvoq bags two new EU approvals
Oral JAK inhibitor approved for psoriatic arthritis and ankylosing spondylitis
Read More
Tag: ankylosing spondylitis
AbbVie submits Rinvoq for ankylosing spondylitis
In a pivotal Phase II/III study, twice as many patients receiving the drug achieved the primary endpoint of ASAS 40 response at week 14 versus placebo
Read More
Lilly bags expanded EU approval for Taltz
Taltz has been granted an additional indication for the treatment of patients across the full axSpA spectrum
Read More
EU green light for new Humira biosimilar
The European Commission has approved Mylan and Fujifilm Kyowa Kirin Biologics’ Humira biosimiar Hulio.
Read More
Gilead, Galapagos’ filgotinib succeeds in PhII ankylosing spondylitis trial
A mid-stage trial assessing Gilead and Galapagos’ JAK 1 inhibitor filgotinib in ankylosing spondylitis has hit its targets.
Read More
Lilly’s Taltz hits goals in PhIII ankylosing spondylitis trial
Regulatory submissions for Lilly’s Taltz in ankylosing spondylitis (AS) are on the cards for later this year after the drug hit primary and secondary targets in a late-stage trial.
Read More
NICE backs wider use of MSD’s Simponi
Cost regulators for therapies funded by the NHS in England and Wales have added MSD’s Simponi (golimumab) to the list of treatments recommended for severe non-radiographic axial spondyloarthritis.
Read More
UK launch for Biogen’s biosimilar infliximab
Biogen has launched Flixabi – a biosimilar of Johnson & Johnson’s blockbuster infliximab – across the UK for use in a range of chronic inflammatory conditions.
Read More
NICE supports Novartis’ Cosentyx for ankylosing spondylitis
National Health Service use of Novartis’ Cosentyx to treat active ankylosing spondylitis is being endorsed by the National Institute for Health and Care Excellence.
Read More
- Wegovy pill launches in UK as first daily oral GLP‑1 for weight management
- Sofinnova reports Myricx Bio to be acquired by Novartis
- Francis Crick Institute and Medicines Discovery Catapult open applications for next KQ Labs cohort
- Novartis receives European Commission approval for Itvisma for spinal muscular atrophy
- AlzeCure enters collaboration agreement with QuantumCell ApS for NeuroRestore project
